Stockscreener 앱 받기
2.27
1.30%
-0.03
전일 마감가:
$2.30
열려 있는:
$2.37
하루 거래량:
14,100
Relative Volume:
0.34
시가총액:
$87.45M
수익:
$24.38M
순이익/손실:
$-53.95M
주가수익비율:
-0.919
EPS:
-2.47
순현금흐름:
$-23.31M
1주 성능:
+6.07%
1개월 성능:
-22.26%
6개월 성능:
-30.58%
1년 성능:
-22.26%
1일 변동 폭
$2.07
$2.37
1주일 범위
$2.05
$2.37
52주 변동 폭
$1.87
$5.24
Elutia Inc Stock (ELUT) Company Profile
명칭
Elutia Inc
전화
240-247-1143
주소
12510 PROSPERITY DRIVE, SILVER SPRING
ELUT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
2.27 | 87.45M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-02 | 개시 | Cowen | Outperform |
| 2020-11-02 | 개시 | Piper Sandler | Overweight |
| 2020-11-02 | 개시 | Truist | Buy |
Elutia Inc 주식(ELUT)의 최신 뉴스
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
Elutia unaffected by global tariffs, maintains US focus - Investing.com Canada
Elutia Unaffected by Global Tariffs Due to US-Based Operations - marketscreener.com
Elutia Confirms No Material Impact from Global Tariffs - The Manila Times
US-Made Medical Devices: How Elutia Dodges Global Tariff Pressures - Stock Titan
Elutia Inc May Offer & Sell Up To $50.0 Million Of Shares Of Class A Common StockSEC Filing - MarketScreener
Elutia Brokers GPO Agreement with Advantus Health Partners - Medical Product Outsourcing
Eluta Slumps on Recognition - Baystreet.ca
EluPro™ Named as 2025 Edison Award Winner - The Manila Times
Revolutionary Medical Device EluPro Clinches Edison Award: Game-Changer for 600,000 Annual Heart Implants - Stock Titan
Elutia to Participate in Upcoming Investor Conferences - TradingView
Exclusive Investor Access: Elutia CEO to Showcase Drug-Eluting Innovation at Premier Conferences - Stock Titan
AIGH Capital Management LLC Has $11.50 Million Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Elutia to Debut EluPro™ at HRS 2025Experience the Difference Biology Makes - The Manila Times
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes - TradingView
Revolutionary Biological CIED Protection: Elutia Unveils Dual-Antibiotic EluPro Technology - Stock Titan
Elutia Inc. reports mixed preliminary 2024 financial results - MSN
Elutia Inc. secures deal with Advantus Health Partners By Investing.com - Investing.com South Africa
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro?? - MarketScreener
Elutia Enters GPO Deal With Advantus Health Partners - MarketScreener
Elutia Inc. secures deal with Advantus Health Partners - Investing.com
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™ - The Manila Times
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro - TradingView
Healthcare Milestone: Elutia Secures 7th GPO Deal for Revolutionary Antibiotic Device - Stock Titan
Elutia publishes new preclinical data in Antibiotics - TipRanks
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope - The Manila Times
Groundbreaking Clinical Data: Elutia's FDA-Cleared Device Eliminates All Tested Bacteria - Stock Titan
Elutia Files For Mixed Shelf Of Up To $100 MillionSEC Filing -March 18, 2025 at 06:23 am EDT - Marketscreener.com
Elutia stock soars, Anteris falls in medical devices sector By Investing.com - Investing.com South Africa
Elutia stock soars, Anteris falls in medical devices sector - Investing.com India
HighCape Capital buys $1.05 million in Elutia Inc. stock - Investing.com India
HighCape Capital buys $1.05 million in Elutia Inc. stock By Investing.com - Investing.com South Africa
Elutia Inc. sees $1.05 million stock purchase by HighCape entities - Investing.com Australia
Elutia Inc. Reports Strong Demand for EluPro™ - TipRanks
ELUTIA INC. SEC 10-K Report - TradingView
Elutia Inc. (ELUT) reports earnings - qz.com
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops By Investing.com - Investing.com Australia
Elutia’s (ELUT) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops - Investing.com India
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out - The Manila Times
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Product Growth ... - Yahoo Finance
Elutia Inc (ELUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
자본화:
|
볼륨(24시간):